Apalutamide Plus Cetrelimab in Patients With Treatment-Emergent Small Cell Neuroendocrine Prostate Cancer
Status:
Not yet recruiting
Trial end date:
2026-05-31
Target enrollment:
Participant gender:
Summary
Despite the low androgen receptor (AR) transcriptional activity of treatment-emergent small
cell neuroendocrine prostate cancer, there is persistent AR expression observed in the
majority of treatment-emergent small-cell neuroendocrine prostate cancer (t-SCNC) biopsies.
This indicates that epigenetic dysregulation leads to reprogramming away from an AR-driven
transcriptional program. Therefore, continuation of AR blockade in the form of apalutamide
may provide additive benefit compared to immune checkpoint blockade alone. The investigators
hypothesize that the combination of apalutamide plus cetrelimab will achieve a clinically
significant composite response rate with sufficient durability of response in mCRPC patients
with evidence of treatment-emergent small cell neuroendocrine prostate cancer